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Summary Sixty-three new untreated patients with multiple myeloma under the age of 70 years received C-VAMP induction treatment
followed by high-dose intravenous melphalan (200 mg m-2) and autologous stem cell transplant, either with marrow [autologous bone marrow
transplants (ABMT), n = 26] or with granulocyte colony-stimulating factor (G-CSF)-mobilized stem cells from the blood [peripheral blood stem
cell transplants (PBSCT), n = 37]. This was a sequential study and the two groups were not significantly different for all known prognostic
variables. The complete remission (CR) rate after high-dose treatment was the same for both groups [ABMT 84% and PBSCT 70%; P= not
significant (NS)]. Neutrophil recovery to 0.5 x 109 I-1 occurred at a median of 22 days in the ABMT patients compared with 19 days for the
PBSCT patients (P = NS). Platelet recovery to 50 x 109 1-1 was significantly faster in PBSCT patients (19 days vs 33 days; P = 0.0015), and
the PBSCT patients spent fewerdays in hospital (median 20 vs 27 days; P= 0.00001). There was no difference in the two groups with respect
to starting interferon (58 days for ABMT vs 55 days for PBSCT), and tolerance to interferon was identical. The median overall survival (OS)
and progression-free survival (PFS) for the PBSCT patients has not yet been reached. The OS in the ABMT patients at 3 years was 76.9%
(95% Cl 60-93%) compared with 85.3% (95% Cl 72-99%) in the PBSCT patients (P= NS), and the PFS at 3 years in the ABMT patients was
53.8% (95% Cl 34-73%) and in the PBSCT patients was 57.6% (95% Cl 34-81%) (P = NS). The probability of relapse at 3 years was 42.3%
in the ABMT arm compared with 40% in the PBSCT patients (P = NS). Thus, PBSCT patients had a faster engraftment and a shorter stay in
hospital than ABMT; the survival outcome and probability of relapse was the same for both groups.
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Myeloablative treatment with alkylating agents is an important
therapeutic option in the treatment of aggressive myeloma
(McElwain and Powles, 1983; Selby et al, 1987; Cunningham et
al, 1994; Barlogie et al, 1995; Harousseau et al, 1995) and a
dose-response effecthas been previously described with the use of
alkylating agents. Though high response rates were noted, this
procedure was associated with considerable haematological toxi-
city; the introduction of autologous bone marrow transplants
(ABMT) countered this toxicity and, in fact, made it possible to
further intensify conditioning regimens (Barlogie et al, 1986; Gore
et al, 1989; Cunningham et al, 1994).
Peripheral blood stem cell transplants (PBSCT) have fast
replaced the use of ABMT because of the potential advantage of
rapid engraftment, less morbidity and cost benefit (Dimopoulos et
al, 1993; Fermand et al, 1993; Powles et al, 1995; Tricot et al,
1995). There has been concern, however, of the efficacy of this
approach because ofpossible tumour cell contamination due to the
mobilization schedules used at the time ofPBSC harvests. Growth
factors such as G-CSF and granulocyte-macrophage colony-
stimulating factor (GM-CSF) have been implicated in the mobiliza-
tion of tumour cells (Rubia et al, 1994). More recently, myeloma
cells have been identified in these harvests as well as in peripheral
blood (Marriette et al, 1994; Belch et al, 1995; Corradini et al,
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1995). The possibility of reinfusion of tumour cells with PBSC
grafts would result in decreased efficacy and would outweigh the
marginal cost benefits overABMT ofearly haemopoietic recovery.
It is therefore crucial to compare ABMT with PBSCT with respect
to relapse and disease-free survival; we report here single-centre
results ofa comparative analysis ofthe two.
PATIENTS AND METHODS
The 63 myeloma patients included in this study were new and
untreated when first seen at the Royal Marsden Hospital between
June 1989 and November 1995. This was from a denominator of
153 new untreated patients under the age of70 seen in this institu-
tion during this time period. The 90 patients excluded from this
analysis include those that belonged to the control arm of our
interferon trial (n = 28; Cunningham et al, 1993), those who
received consolidation with either melphalan alone or busulfan
(n = 14) and those who did not receive high-dose treatment for
various reasons (n = 48). Table 1 shows the demographic distribu-
tion of age, sex, stage, performance status, creatinine and 32
microglobulin at presentation.
Induction treatment
All 63 patients received courses of infusional chemotherapy,
which included vincristine 0.4 mg i.v. by continuous infusion over
24 h for 4 days, doxorubicin 9 mg m-2 i.v. by continuous infusion
over24 h for4 days and methyl prednisolone 1.5 gm i.v. orp.o. for
4 days and then tapered and weekly cyclophosphamide (C-VAMP)
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Table 1 Patient demographics
Patient characteristic ABMT (n = 26) PBSCT (n = 37)
Age (years)
< 50 12 (46) 17 (46)
> 50 14 (54) 20 (54)
Median 50 49
Range 40-67 37-63
Sex
Male 16 (62) 23 (62)
Female 10 (38) 14 (38)
Stage
IA 6 (23) 5 (14)
IIA 1(4) 4(10)
IIIA 14 (54) 23(62)
IIIB 5 (19) 5 (14)
Performance status
0 20 (77) 21 (57)
1 6 (23) 14 (38)
2 0(0) 2(5)
Serum creatinine
(lmol 1-')
< 130 25(96) 35(95)
130-200 1 (4) 2 (5)
02-microglobulin
(mg 1-)
<3 21 (81) 24(65)
>3 5 (19) 13 (35)
No significant difference by the Kruskal-Wallis test and chi-square test.
Numbers in parentheses are percentages.
Table 2 Response to C-VAMP induction treatment and after high-dose
treatment
Response ABMT (n = 26) PBSCT (n = 37) P-value
C-VAMP induction treatment
Complete remission 7 (27) 12 (32) NS
Partial remission 16 (61) 17 (46) NS
No response 3 (12) 8 (22) NS
After high-dose treatment
Complete remission 22 (84) 26 (70) NS
Partial remission 2 (8) 10 (27) NS
No response 2 (8) 1 (3) NS
NS, not significant. Numbers in parentheses are percentages.
Table 3 Comparison of two harvest protocols used in PBSCT (protocol A
and protocol B)
Protocol A Protocol B P-value
(n=14) (n=23)
Mononuclear cells (x 108 cells kg-') 8.54 4.1 0.00
Range 2.26-11.91 2.37-9.14
CD 34+ cells (x 106 cells kg-1) 5.65 0.5745 0.002
Range 0.05-31.6 (0.002-6.96)
GM-CFU (x 104 cells kg-') 6.62 3.085 0.04
Range 1.58-38.62 0.02-24.95
Platelet recovery (days)a 18 19 > 0.1
Range 13-40 12-148
Neutrophil recovery (days)b 17 19 > 0.1
Range 12-42 14-40
aPlatelet recovery to 50 x 109 I-'. bNeutrophil recovery to 0.5 x 109 I-1
as initial treatment following diagnosis (Raje et al, 1995). These
courses were repeated every 21 days until plateau response
occurred (see below) or the patients went into complete remission
(CR). One further course was then given.
High-dose treatment
Approximately 6 weeks after the start of the last chemotherapy
cycle, high-dose treatment and an autograft with bone marrow or
peripheral blood stem cells was given. Conditioning comprised
melphalan (200 mg m-2 infusion over 30 min) on day -1 if EDTA
was > 40 ml min-'. Adequate hydration before and after high-dose
treatment with melphalan was ensured to maintain a urine output of
20 ml min-' 1 h afterhigh dose and 500 ml h-I in the subsequent 2 h.
ABMT
Between January 1989 and May 1992, 26 patients received an
ABMT. Marrow was harvested as an inpatient under general
anaesthesia, just before high-dose treatment. The target total
nucleated cell collection was 2-5 x 108 cells per kg of body
weight. Marrow was stored following controlled cooling to
- 140°C with 5% dimethylsulphoxide (DMSO) and stored in the
vapour phase of liquid nitrogen. When required, it was rapidly
thawed at 37°C and reinfused immediately without further
processing.
PBSCT
Between May 1992 and November 1995, 37 patients received
PBSCTs using stem cells mobilized with recombinant human
granulocyte colony-stimulating factor (rhG-CSF), all harvests
being undertaken as a day case/outpatient procedure.
Protocol A
Between May 1992 and June 1994 PBSC mobilization was
achieved using home administration of subcutaneous rhG-CSF
(Amgen) at a dose of 125 gg m-2 12 hourly for 7 days (14 doses) 6
weeks after the last chemotherapy cycle andjust before the high-
dose treatment. Leucapheresis was performed on 4 consecutive
days, starting on day 5 (days 5-8) using the Cobe separator, and
all cells collected were cryopreserved and reinfused after thawing.
Fourteen patients received protocol A.
Protocol B
From June 1994, G-CSF was given at a dose of 12-16jig kg-' for
4 days, followed by leucapheresis on 2 consecutive days starting
on day 4. Twenty-three patients received this protocol.
Flow cytometry and GM-CSF assays
Aliquots of each PBSC harvest were counted and used for flow
cytometric analysis within 2 h of collection. Mouse anti-human
antibodies were used.
Light-density mononuclear cells were plated in soft agar at a
concentration of 5 x 105 per dish using a double-layer technique,
with 100 ,ul of 5637 conditioned medium in the underlay as a
source ofGM-CSF. Cultures were plated in triplicate, incubated at
37°C in a humidified atmosphere and the colonies counted at
12-14 days using an inverted microscope.
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Transplantation
Patients were admitted on the day they received the high-dose
melphalan and transplants were usually undertaken in a four-
bedded ward. This protocol had been approved by the hospital
clinical research ethics committee and all patients signed an
informed consent before recruitment. Prophylactic broad spectrum
parenteral antibiotics were started routinely on the 5th day after
transplant. Patients were discharged, if well, once the absolute
neutrophil count reached 0.5 x 109 1-' and they no longer needed
intravenous antibiotic support. No growth factors were used in the
post transplant setting. The criteria for discharge were uniform
throughout the programme.
Maintenance interferon
After high-dose treatment, patients were started on maintenance
interferon alpha (3 megaunits m-2 3 x weekly, S/C- Schering
Plough) initially as part of a randomized trial (Cunningham et al,
1993; Powles et al, 1995) and subsequently in allpatients when the
WBC count reached 2 x 109 1-1 and platelet count 50 x 1091-. The
dose of interferon was reduced or stopped according to haemato-
logical criteria or other toxic manifestations.
Response and relapse criteria
Our response criteria and definition of CR have been described
earlier (Gore et al, 1989). Four criteria had to be met for a patient
to be regarded as having achieved CR: (1) no paraprotein measur-
able by scanning densitometry of serum proteins separated on
cellulose acetate membrane by electrophoresis and stained with
Ponceau S; (2) no detectable Bence-Jones proteinuria on elec-
trophoresis of neat urine stained with colloidal gold; (3) 5% or
fewer plasma cells ofnormal morphology on bone marrow aspira-
tion; and (4) criteria 1-3 had to be fulfilled for at least 3 months.
Patients were regarded as having achieved a partial response (PR)
ifthere was a 50% decrease in measurable paraprotein (IgG orIgA
myeloma) or bone marrow infiltration (non-secretory or Bence-
Jones myeloma) that was sustained for a month or more. Relapse
was defined as reappearance ofparaprotein or bone marrow infil-
tration ofmore than 5% forpatients in CR and as a 25% increase in
measurable paraprotein in two samples 1 month apart for patients
in PR. No response (NR) was considered if the patient failed to
achieve a CR or a PR.
Statistical considerations
Patient characteristics in the two arms were compared using the
chi-square and Kruskal-Wallis test (Kruskal and Wallis, 1952).
Engraftment data were plotted using Kaplan-Meier (Kaplan and
Meier, 1958) life table curves, and comparisons were made using
the log-rank test (Peto and Peto, 1972). The duration of response
was measured from the date ofstartofinduction treatment. Overall
and progression-free survivals were plotted using the Kaplan-
Meier method, and comparisons were again made using the log-
rank method.
RESULTS
Data have been analysed in April 1996 with a median follow-up of
30 months. The median follow-up in the PBSCT patients is 25
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Figure 3 Life table curves of in-hospital stay. P= 0.0000
months with the minimum follow-up being 6 months. Patient
demography is described in Table 1, and the distribution ofknown
prognostic criteria was the same for both groups.
Induction treatment
Patients received induction with C-VAMP chemotherapy. The
ABMT group ofpatients received a median offive courses (range
3-7), while the PBSCT group received a median of six courses
of chemotherapy (range 1-8) before consolidation with high-
dose treatment; this difference was not significant. Details of
response to induction treatment are shown in Table 2 and are
similar in the two arms, with an overall response before
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Figure 5 Progression-free survival from start of induction treatment. P = NS
high-dose treatment of 88.4% in the ABMT and of 78.3% in the
PBSCT patients (P = NS).
Autologous stem cell transplants
Twenty-six patients received an ABMT and are compared with 37
patients who received a PBSCT. The median total nucleated cell
dose returned in the ABMT patients was 2.16 x 108 cells kg-'
(range 1.11-2.26 x 108 cells kg-1). The median cell dose returned
in the PBSCT patients was 5.1 x 108 cells kg-' (range 2.26-
11.91 x 108 cells kg-'). Details of response following high-dose
treatment are shown in Table 2 and are similar in the two arms.
For PBSCT harvests, 14 patients underwent mobilization with
protocol A and 23 patients with protocol B. Details of the quality
of their harvests are shown in Table 3. Even though both CD 34+
numbers and the GM-CFUs were significantly different in the two
groups, engraftment was no different. Neutrophil recovery to
0.5 x 1091- occurred at a median of 17 days (range 12-42 days) in
protocol A vs 19 days (range 14-40 days) in protocol B (P = NS).
Platelet recovery to 50 x 1091-1 was also similar (median 18 days,
range 13-40 days vs median 19 days, range 12-148 days; P = NS).
There was no difference with respect to survival outcome and
relapse in these two groups and therefore subsequent analysis has
been undertaken with the two groups combined.
Engraftment and days in hospital
Figures 1 and 2 show the time to neutrophil and platelet recovery
respectively. A median of 22 days (range 12-38 days) was
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Figure 6 Probability of starting interferon after high-dose treatment. P= NS
required to reach a neutrophil count of 0.5 x 1091- in the ABMT
group compared with 19 days (range 12-42 days) in the PBSCT
group (P = NS). Platelet recovery to 50 x 1091-' was significantly
faster in the PBSCT patients with medians reached at 19 days
(range 12-148 days) compared with 33 days (range 18-72 days) in
the ABMT patients (P = 0.0015).
The ABMTpatients spent a median of27 days inhospital, while
the PBSCT patients spent a median of 20 days from transplant
(P = 0.00001) (Figure 3).
Survival and relapse
Figures 4 and 5 show the overall survival (OS) and progression-
free survival (PFS) in the two groups ofpatients. The median OS
and PFS for the PBSCT has not yet been reached. Of the ABMT
patients, 76.9% (95% CI 60-93%) compared with 85.3% (95% CI
72-99%) ofthe PBSCT patients are alive at 3 years (P = NS). Of
the ABMT patients, 53.8% (95% CI 34-73%) do not have
evidence of disease progression at 3 years compared with 57.6%
(95% CI 34-81%) of the PBSCT patients (P = NS). The proba-
bility ofrelapse at 3 years was 42.3% in the ABMT arm vs 40% in
the PBSCT arm (P = NS). Within the PBSCT arm, there was no
difference in the OS and PFS between patients receiving either
protocol A or protocol B.
Interferon maintenance
Interferon maintenance was started at a median of 58 days (range
33-146 days) in the ABMT patients and a median of 55 days
(range 20-181 days) in the PBSCT patients (P = NS) (Figure 6)
and was continued until relapse. Tolerance to interferon was
similar in the two groups. The commonest side-effect was flu-like
symptoms and was seen in 60% ofthe patients in both arms. Other
side-effects, such as headache (one patient in each arm), skin prob-
lems (one patient in ABMT arm and two patients in PBSCT arm),
diarrhoea (one patient in each arm) and sexual problems (three
patients in the ABMT arm and one patient in the PBSCT arm)
were rarely seen. Two patients in the ABMT arm discontinued
interferon treatment, one because of depression and the other
because ofpetit mal seizures. Similarly, two patients belonging to
the PBSCT group also discontinued treatment, the reasons being
depression and psoriasis. Dose modification was seen in 11
ABMT and 13 PBSCT patients.
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DISCUSSION
High-dose alkylating chemotherapy with haemopoietic rescue is
being used more frequently as consolidation therapy for myeloma,
and blood-derived stem cells (Fermand et al; 1993; Attal et al,
1995; Harousseau et al, 1995a; Powles et al, 1995) have become
increasingly the method used, but as yet the significance oftumour
cell contamination in PBSCT is unknown.
The French Registry has previously reported on a retrospective
comparison of ABMT and PBSCT (Harrousseau et al, 1995b).
These comparisons were made in patients belonging to 18 French
centres with significant demographic differences in the two groups
with respect to patient age and chemotherapy before transplant,
giving a better prognostic bias to the PBSCT cohort. No signifi-
cant difference was noted by them with respect to response and
survival outcome.
We have compared the two procedures at a single centre with no
difference in the prognostic variables in the two groups. All
patients have received identical induction treatment and condi-
tioning regimens. The only difference in the two groups was the
source of the stem cells. Our data show a more rapid platelet
recovery in the PBSCT group than in the ABMT group (19 days vs
33 days), but neutrophil recovery was not significantly different
(19 days vs 22 days). However, our PBSCT patients had a signifi-
cantly shorter hospital stay. This was not because ofany change in
our discharge criteria and it remains unclear why our PBSC
patients left hospital earlier. Comparison of our results with the
French data (Harousseau et al, 1995b) shows some important
differences. They show a more rapid neutrophil recovery in the
PBSCT arm (13 days vs 22 days; P < 0.001) and no significant
difference in platelet recovery (26 days in PBSCT patients vs 22
days in ABMT patients). This could be attributed to differences in
mobilization schedules used. We have used growth factors
alone for mobilization, whereas the French study had harvested
PBSC after chemo-induced aplasia and without priming with
haematopoietic growth factors. Our results also show a delay of
about 5-8 days with respect to neutrophil recovery in our PBSCT
group compared with other series (Fermand et al, 1993;
Harousseau et al, 1995b). This could well be because of the low
numbers of CD34+ cells and GM-CFU counts in our PBSCT
harvests and highlights the fact that mononuclear counts are not
good indicators ofthe quality ofgraft.
Our CR rate was not significantly different in the two arms
(70% vs 84%). The lower CR rate in the PBSCT arm may be the
result ofa shorter follow-up in the PBSCT patients, because it can
take as long as 786 days (Singhal et al, 1995) for paraprotein to
disappear following high-dose treatment. Our minimum follow-up
in the blood stem cell patients is 6 months, and there is the theoret-
ical possibility of seeing more patients achieving CR beyond 6
months because ofthe biology ofthe disease.
Reinfusion ofthe malignant clone is a majorconcern in all auto-
grafting procedures. Corradini et al (1995) have demonstrated, by
a polymerase chain reaction (PCR)-based strategy using clone-
specific sequences derived from the rearrangement of IgH genes,
the presence of both pre-and post-switch B cells in bone marrow
and blood stem cell harvests. Whether or not these cells contribute
to relapse is debatable. Their data suggest that blood-derived stem
cell harvests may have a lower rate ofcontamination.
Limited data are available on the optimal dose and quality of
PBSC harvests required for adequate engraftment and, although
various investigators have identified favourable predictors of
engraftment (Tricot et al, 1995; Demirer et al, 1996), the minimum
dose required for engraftment is unknown. However it seems
logical that a lower dose ofhaemopoietic stem cells will relate to a
lower reseeding with malignant cells. A dose of 5 x 106 CD34+
cells kg-' has been identified as adequate (Bensinger et al, 1994)
forrapid engraftment, but we have seen sustained engraftment with
significantly lower doses ofCD 34+ cells. Newer approaches such
as positive selection of stem cell harvests are being applied (Gazitt
et al, 1995; Schiller et al, 1995) and a comparison of CD34+
selected vs unselected PBSCT will be crucial in identifying a
superior quality graft in myeloma. Retroviral marking of CD34-
enriched harvests has been undertaken in myeloma (Dunbar et al,
1995) and will undoubtedly be an area for future therapeutic trials.
The OS and PFS in our patients compare favourably with those
reported by other investigators. The University of Arkansas
(Barlogie et al, 1995) have reported amedian OS of40 months and
a median event-free survival of 23 months in 287 patients who
have undergone autotransplants. The French registry has reported
a median OS of 54 months in responding patients with a median
remission duration of 33 months (Harousseau et al, 1995a).
Fermand et al (1993) have reported a median OS of 59 months
and a median event-free survival of43 months. We were unable to
see a significant survival disadvantage from the use of G-CSF-
generated stem cells, obviating the concern of mobilization and
reseeding by the PBSCT oftumour cells.
Interferon maintenance following high-dose treatment has
shown benefit (Cunningham et al, 1993; Powles et al, 1995) to
patients after autografting, and it is important that the PBSC graft
should tolerate its use. We havepreviously documented the robust-
ness ofperipheral blood stemcells to interferon therapy (Powles et
al, 1996), and this study confirms that interferon could be started
on all patients receiving a PBSCT and that it was as well tolerated
in this group as in the ABMT group.
What happens to the patient after autografting is dictated by the
remaining disease cells in the host and slight variations in trans-
plant procedures, i.e. ABMT or PBSCT, which even though
capable ofinfluencing engraftment, may not influence the ultimate
outcome. All autograft strategies will, however, be effective only
ifit is possible to further escalate high-dose regimens to eliminate
residual disease.
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